# A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV

> **NCT06812494** · PHASE2 · RECRUITING · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 200 (estimated)

## Conditions studied

- HIV

## Interventions

- **BIOLOGICAL:** VRC07-523LS 400mg
- **BIOLOGICAL:** PGT121.414.LS 400mg
- **BIOLOGICAL:** PGDM1400LS 400mg
- **BIOLOGICAL:** VRC07-523LS 3200mg
- **BIOLOGICAL:** PGT121.414.LS 1600mg
- **BIOLOGICAL:** PGDM1400LS 1600mg

## Key facts

- **NCT ID:** NCT06812494
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-07
- **Primary completion:** 2027-01-15
- **Final completion:** 2027-09-15
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06812494

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06812494, "A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIV". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06812494. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*